↓ Skip to main content

Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer

Overview of attention for article published in BMC Cancer, November 2017
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
15 Mendeley
Title
Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer
Published in
BMC Cancer, November 2017
DOI 10.1186/s12885-017-3691-9
Pubmed ID
Authors

Cemile Dilara Savci-Heijink, Hans Halfwerk, Jan Koster, Marc Joan Van de Vijver

Abstract

To better predict the likelihood of response to chemotherapy, we have conducted a study comparing the gene expression patterns of primary tumours with their corresponding response to systemic chemotherapy in the metastatic setting. mRNA expression profiles of breast carcinomas of patients that later developed distant metastases were analyzed using supervised and non-supervised classification techniques to identify predictors of response to chemotherapy. The top differentially expressed genes between the responders and non-responders were identified and further explored. An independent dataset which was generated to predict response to neo-adjuvant CT was utilized for the purpose of validation. Response to chemotherapy was also correlated to the clinicopathologic characteristics, molecular subtypes, metastatic behavior and survival outcomes. Anthracycline containing regimens were the most common first line treatment (58.4%), followed by non-anthracycline/non-taxane containing (25.8%) and taxane containing (15.7%) regimens. Response was achieved in 41.6% of the patients to the first line CT and in 21.8% to second line CT. Response was not found to be significantly correlated to tumour type, grade, lymph node status, ER and PR status. Patients with HER2+ tumours showed better response to anthracycline containing therapy (p: 0.002). Response to first and second line chemotherapy did not differ among gene expression based molecular subtypes (p: 0.236 and p: 0.20). Using supervised classification, a 14 gene response classifier was identified. This 14-gene predictor could successfully predict the likelihood of better response to first and second line CT (p: <.0001 and p: 0.761, respectively) in the training set. However, the predictive value of this gene set in data of response to neoadjuvant chemotherapy could not be validated. To our knowledge, this is the first study revealing the relation between gene expression profiles of the primary tumours and their chemotherapy responsiveness in the metastatic setting. In contrast to the findings for neoadjuvant chemotherapy treatment, there was no association of molecular subtype with response to chemotherapy in the metastatic setting. Using supervised classification, we identified a classifier of chemotherapy response; however, we could not validate this classifier using neoadjuvant response data. Non applicable. Subjects were retrospectively registered.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 20%
Researcher 3 20%
Student > Bachelor 2 13%
Other 2 13%
Student > Master 2 13%
Other 3 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 5 33%
Unspecified 3 20%
Biochemistry, Genetics and Molecular Biology 3 20%
Medicine and Dentistry 3 20%
Immunology and Microbiology 1 7%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2017.
All research outputs
#10,797,931
of 12,177,594 outputs
Outputs from BMC Cancer
#3,617
of 4,459 outputs
Outputs of similar age
#272,427
of 325,684 outputs
Outputs of similar age from BMC Cancer
#92
of 109 outputs
Altmetric has tracked 12,177,594 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,459 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,684 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 109 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.